ホーム>>PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt) (Synonyms: Pituitary Adenylate Cyclase-activating Peptide (1-38))

カタログ番号GC44532

下垂体アデニル酸シクラーゼ活性化ペプチド(PACAP)(1-38)は、CHO細胞で発現したラットPAC1、ラットVPAC1、およびヒトVPAC2再構成受容体に対してそれぞれIC50値が4、2、および1 nMのPACAP受容体作動薬です。

Products are for research use only. Not for human use. We do not sell to patients.

PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt) 化学構造

サイズ 価格 在庫数 個数
500μg
$677.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pituitary adenylate cyclase-activating peptide (PACAP) (1-38) is a PACAP receptor agonist with IC50 values of 4, 2, and 1 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors in rat brain membrane (IC50 = 4.45 nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 3.6, 13, and 4.7 nM, respectively). It also stimulates cAMP accumulation in H-SY5Y, SK-N-MC, and T47D cells (EC50s = 0.37, 0.26, and 0.73 nM, respectively). In vivo, in newborn pigs, PACAP (1-38) (1 μM) induces vasodilation of pial arterioles by 43%.

レビュー

Review for PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.